Dr. Teal brings 28 years of leadership and scientific research experience to Ashland's board. Prior to her retirement from Avon in 2010, she led the company's global research and development team of chemists and scientists, with responsibility for the development and support of Avon's worldwide product lines. Before that, she served as VP of the Avon Skin Care Laboratories, where she led the bioscience research and skin care teams that ultimately led to the growth of the Anew Skin Care brand to more than $1 billion in sales. She had additional responsibility for development of Avon's vitamin and nutritional lines.
Dr. Teal joined Avon in 1982 as a program leader in toxicology and built Avon's first pharmacokinetics and cell culture laboratories. She earned a Ph.D. in pharmacology from Emory University and served as a Research Fellow in toxicology at New York University. She previously served on the board of directors of Arch Chemicals, which was acquired last year by Lonza Group Ltd. In addition to serving on the Ashland board, she is a trustee of Dominican College.
Ashland provides specialty chemicals, technologies, and insights in a wide variety of markets and applications, including tissue and towel, architectural coatings, automotive, construction, energy, food and beverage, personal care, pharmaceutical, and water treatment. The company operates through four commercial units: Ashland Specialty Ingredients, Ashland Water Technologies, Ashland Performance Materials, and Ashland Consumer Markets.
TAPPI
http://www.tappi.org/